AUS
NZ
UK
CA
USA
IND
Highlights
- Sonic Healthcare has seen a decline of 6.2% since the start of 2025, while (ASX:PME) remains 25.7% below its 52-week high.
- Sonic Healthcare is a global leader in pathology and diagnostic services, serving multiple regions.
- Pro Medicus specializes in advanced radiology software solutions, driving innovation in medical imaging.
Healthcare Sector Insights
The healthcare sector continues to evolve, with advancements in technology and diagnostic capabilities reshaping medical services. Two notable players in this space, Sonic Healthcare (ASX:SHL) and Pro Medicus (ASX:PME), are well-positioned in their respective fields.
Sonic Healthcare is one of the world’s largest pathology businesses, offering services across Australia, New Zealand, Europe, and North America. The company specializes in laboratory medicine, pathology, radiology, and corporate medical services, supporting healthcare providers with essential diagnostic solutions. Established in 1987, the company has a long-standing reputation for medical excellence and a commitment to improving patient care.
Pro Medicus, on the other hand, focuses on radiology software solutions. The company provides hospitals, imaging centers, and healthcare networks with a suite of advanced tools, including Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and visualization technology. The Visage software by Pro Medicus allows radiologists to remotely access large imaging files, enabling faster and more efficient diagnostic processes. This capability enhances the speed and accuracy of medical evaluations, contributing to improved patient outcomes.
Stock Performance and Financial Metrics
The market performance of these healthcare companies has seen fluctuations in 2025. Since the beginning of the year, Sonic Healthcare has declined by 6.2%, while Pro Medicus remains 25.7% below its 52-week high.
Financially, Sonic Healthcare reported revenue growth of 0.8% annually since 2021, reaching $8,967 million in FY24. However, net profit has decreased from $1,315 million to $511 million during the same period. The return on equity (ROE) currently stands at 6.8%, reflecting the company's ability to generate returns from its assets.
Meanwhile, Pro Medicus has demonstrated stronger growth, with revenue rising at an annual rate of 33.4% over the last three years to $162 million in FY24. Net profit has also seen a significant rise, growing from $31 million to $83 million. The company’s ROE is an impressive 50.7%, indicating strong profitability.
Final Thoughts
The healthcare sector continues to present opportunities for growth, driven by innovation in diagnostic services and medical technology. While Sonic Healthcare maintains its position as a global leader in pathology and laboratory services, Pro Medicus is making strides with its cutting-edge radiology software. Monitoring the performance and developments of these companies could provide valuable insights into the evolving healthcare landscape.
